

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 March 2018 (15.03.2018)



(10) International Publication Number
WO 2018/048937 A1

(51) International Patent Classification:

C07H 23/00 (2006.01) C07H 19/207 (2006.01)
C07H 19/16 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2017/050323

(22) International Filing Date:

06 September 2017 (06.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/384,664 07 September 2016 (07.09.2016) US

(71) Applicant: ATEA PHARMACEUTICALS, INC.
[US/US]; 125 Summer Street, Boston, MA 02110 (US).

(72) Inventors: SOMMADOSSI, Jean-Pierre; c/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US). MOUSSA, Adel; c/o Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA 02110 (US).

(74) Agent: BELLOWS, Brent, R.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: 2'-SUBSTITUTED-N⁶-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT

(57) Abstract: The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.



WO 2018/048937 A1